newsfilter
← Latest News
Business Wire·

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent Therapeutics reinforces Ipsen's expansion into hematolog